Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 25 15 versus ORETICYL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 25 15 versus ORETICYL FORTE.
CAPOZIDE 25/15 vs ORETICYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of captopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and reducing plasma volume.
Thiazide diuretic; inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Oral: 1 tablet (captopril 25 mg / hydrochlorothiazide 15 mg) once daily initially; titrate to a maximum of 2 tablets twice daily based on blood pressure response.
Hydrochlorothiazide (HCTZ) 50 mg and deserpidine 0.5 mg orally once daily.
None Documented
None Documented
Captopril: ~2 hours (terminal) in normal renal function; increases to 20-60 hours in severe renal impairment. Hydrochlorothiazide: 6-15 hours (terminal), prolonged in renal impairment.
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Deserpidine: 4-12 hours.
Captopril: 95% renally excreted, primarily as unchanged drug and metabolites (disulfide dimers). Hydrochlorothiazide: at least 95% renally excreted as unchanged drug.
Renal excretion: ~70% as hydrochlorothiazide unchanged; ~30% as deserpidine metabolites via bile/feces.
Category C
Category C
ACE Inhibitor and Diuretic Combination
Diuretic Combination